Signature Estate & Investment Advisors LLC Has $755,000 Stake in Thermo Fisher Scientific Inc. $TMO

Signature Estate & Investment Advisors LLC lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 40.1% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,505 shares of the medical research company’s stock after selling 1,009 shares during the quarter. Signature Estate & Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $755,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Legacy Wealth Managment LLC ID raised its holdings in shares of Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 22 shares during the period. Allied Private Wealth LLC acquired a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $26,000. High Note Wealth LLC boosted its holdings in Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after acquiring an additional 29 shares in the last quarter. Swiss RE Ltd. bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $28,000. Finally, JPL Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific during the third quarter worth approximately $28,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the transaction, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. This represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $71,191,194.75. This represents a 7.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 52,053 shares of company stock valued at $30,643,589. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on TMO shares. Jefferies Financial Group reissued a “buy” rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Royal Bank Of Canada raised their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research report on Friday, July 24th. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a report on Monday, July 6th. Wolfe Research started coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective for the company. Finally, Barclays lifted their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $596.65 on Friday. The business’s fifty day simple moving average is $527.07 and its 200 day simple moving average is $509.02. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The firm has a market capitalization of $220.61 billion, a P/E ratio of 32.10, a price-to-earnings-growth ratio of 2.45 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is currently 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.